EP4456901A1 - Composition pharmaceutique d'empagliflozine et de linagliptine traitée par extrusion à chaud - Google Patents

Composition pharmaceutique d'empagliflozine et de linagliptine traitée par extrusion à chaud

Info

Publication number
EP4456901A1
EP4456901A1 EP22917050.1A EP22917050A EP4456901A1 EP 4456901 A1 EP4456901 A1 EP 4456901A1 EP 22917050 A EP22917050 A EP 22917050A EP 4456901 A1 EP4456901 A1 EP 4456901A1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
composition according
salts
linagliptin
empagliflozin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22917050.1A
Other languages
German (de)
English (en)
Other versions
EP4456901A4 (fr
Inventor
Burcin YANC
Muge ULUSOY BOZYEL
Fatih Sunel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Priority claimed from PCT/TR2022/051598 external-priority patent/WO2023129050A1/fr
Publication of EP4456901A1 publication Critical patent/EP4456901A1/fr
Publication of EP4456901A4 publication Critical patent/EP4456901A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Definitions

  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprises a granulate comprising empagliflozin or salts thereof and linagliptin or salts or crystalline polymorph thereof, wherein the granulate is obtained by hot melt extrusion.
  • Diabetes mellitus is a group of disorders of carbohydrate metabolism in which the action of insulin is diminished or absent through altered secretion, decreased insulin activity or a combination of both factors.
  • Type 1 and Type 2 There are two main types of diabetes; Type 1 and Type 2:
  • Type 1 diabetes occurs because the insulin-producing cells of the pancreas (beta cells) are damaged. In Type 1 diabetes, the pancreas makes little or no insulin, so sugar cannot get into the body's cells for use as energy. People with Type 1 diabetes must use insulin injections to control their blood glucose.
  • Type 2 diabetes the pancreas makes insulin, but it either doesn't produce enough, or the insulin does not work properly. This diabetes occurs most often in people who are over 40 years old and overweighed. Type 2 diabetes may sometimes be controlled with a combination of diet, weight management, and exercise. However, treatment also may include oral glucose-lowering medications or insulin injections.
  • Linagliptin is used for type 2 or non-insulin dependent diabetes. It is a selective, orally administered, xanthine based dipeptidyl peptidase-4 (DPP-4) inhibitor used as an adjunct to diet and exercise to improve glycemic control. DPP-4 inhibitors work by blocking the action of DPP-4, an enzyme which destroys the hormone incretin.
  • DPP-4 inhibitors work by blocking the action of DPP-4, an enzyme which destroys the hormone incretin.
  • DPP-4 inhibitors work by blocking the action of DPP-4, an enzyme which destroys the hormone incretin.
  • GLP-1 glucagon-like peptide-1
  • GIP glucose-dependent insulinotropic peptide
  • Linagliptin works by binding to DPP-4 and preventing it from breaking down the GLP-1 and GIP. This increases the levels of these hormones in the body and so increases their effect on controlling blood sugar.
  • the chemical name of linagliptin is 8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-yn-1-yl)-3-methyl-1- [(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2, 6-dione and its chemical structure is shown in the Formula I.
  • Empagliflozin is a known SGLT2 inhibitor that is described for the treatment or improvement in glycemic control in patients with type 2 diabetes mellitus.
  • the chemical name of empagliflozin is 1 -chloro-4-(3-D-glucopyranos-1 -yl)- 2-[4-((S)-tetrahydrofuran-3-yloxy)- benzylj-benzene and its chemical structure is shown in the Formula II.
  • Tablets of empagliflozin in combination with linagliptin for oral administration are currently being marketed in United States under the name Glyxambi® by Boehringer Ingelheim indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and are available as single layer tablets in two dosage strengths i.e. 10 mg/5 mg and 25 mg/5 mg respectively.
  • Patent publication describes pharmaceutical compositions of linagliptin, their preparation and their use in the treatment of type 1 diabetes mellitus and type 2 diabetes mellitus.
  • Patent publication discloses single layered pharmaceutical compositions comprising combination of empagliflozin and linagliptin.
  • a pharmaceutical composition comprising empagliflozin or salts thereof and linagliptin or salts or crystalline polymorph thereof in oral pharmaceutical dosage forms.
  • the main object of the present invention is to provide a pharmaceutical composition comprising empagliflozin or salts thereof and linagliptin or salts or crystalline polymorph thereof having the desired content uniformity and the desired dissolution profile by the help of selection of excipients using an effective process and bringing additional advantages to the relevant prior art.
  • the content uniformity of low dose drugs in dosage forms is very important for quality assurance.
  • the advantages of the present invention are even more significant, as the problem of homogeneity is even more likely to occur when two active substances are incorporated in one final dosage form, especially when two actives is used very different regarding the amount.
  • Improved content uniformity efficiently contributes to a marked increase in bioavailability.
  • Improved content uniformity also favors to avoid toxicity in the otherwise possible event that the amount of drug substance would be too high.
  • Linagliptin is used small proportion that can lead to important problems during the process of the formulation. This causes the content uniformity problems and this causes dissolution problem.
  • using hotmelt extrusion process provides homogeneity and content uniformity which would not lead to losses in the linagliptin or excipients during production.
  • a pharmaceutical composition comprises granulates comprising empagliflozin or salts thereof and linagliptin or salts or crystalline polymorph thereof, wherein the granulates is obtained by hot melt extrusion.
  • granules is obtained that at the end of the hot melt extrusion, extrudates form is converted to granules.
  • a d (0.9) particle size of obtained extrudate using hot melt extrusion is less 250 pm, more preferably it is less 200 pm.
  • the size of the extrudate provides surprisingly better solubility and stability.
  • the total amount of empagliflozin or salts thereof is between 5.0% and 30.0% by weight of the total composition.
  • the total amount of empagliflozin or salts thereof is between 7.0% and 25.0% or 13.0% and 20.0% by weight of the total composition.
  • the total amount of linagliptin or salts or crystalline polymorph thereof is between 0.5% and 8.0% by weight of the total composition.
  • the total amount of linagliptin or salts or crystalline polymorph thereof is between 1.3% and 6.0% or 2.0% and 5.0% by weight of the total composition.
  • Empagliflozin have melting points in the range of about 145°C to 160°C. Preferably, melting points of empagliflozin is 153°C.
  • Linagliptin have melting points in the range of about 198°C to 206°C. Preferably, melting points of empagliflozin is 202°C.
  • the granulates further comprises at least one filler.
  • Suitable fillers are selected from the group comprising polyvinylpyrrolidone, dibasic calcium phosphate, microcrystalline cellulose, lactose monohydrate, ammonium alginate, calcium carbonate, calcium phosphate, calcium phosphate dehydrate, neutral pellets, calcium sulfate, cellulose, cellulose acetate, compressible sugar, dextrates, dextrin, dextrose, ethylcellulose, fructose, glyceryl palmitostearate, lactose, mannitol, magnesium carbonate, magnesium oxide, maltodextrin, medium chain triglycerides, polydextrose, polymethacrylates, simethicone, sodium alginate, sodium chloride, sugar spheres, sulfobutylether betacyclodextrin, talc, tragacanth, trehalose, xylitol or mixtures thereof.
  • the filler is polyvinylpyrrolidone or dibasic calcium phosphate or mixtures thereof.
  • the amount of the filler is between 50.0% to 90.0% by weight of the total composition.
  • the amount of the filler is between 55.0% to 88.0% or 65.0% to 88.0% by weight of the total composition.
  • the pharmaceutical composition comprises;
  • the amount of granulate is at least 95.0% by weight of the total composition and the granulate comprising;
  • the amount of at least one pharmaceutically acceptable excipient is between 0.05% to 5.0% by weight of the total composition.
  • the pharmaceutical composition comprises granulates and at least one pharmaceutically acceptable excipient which selected from the group comprising glidants, lubricants or mixtures thereof.
  • Suitable glidants are selected from the group comprising colloidal silicon dioxide, polyethylene glycol, triacetin, alpha tocopherol, docusate sodium, glyceryl monooleate, glyceryl monostearate, phospholipids, polyoxylglycerides, triethyl citrate, tributyl citrate, acetyl triethyl citrate, acetyl tributyl citrate, butyl stearate, stearyl alcohol, propylene glycol, diethyl phthalate, dibutly phthalate, dioctyl phosphate, sodium lauryl sulphate, potassium cetylphosphate, ethylene glycol distearate, sodium dodecanoate, dioctyl sodium sulfosuccinate, sodium stearate, benzalkonium chlorides, polysorbates, poloxamers or mixtures thereof.
  • the glidant is colloidal silicon dioxide.
  • the amount of the glidant is between 0.05% to 3.0% by weight of the total composition.
  • Suitable lubricants are selected from group comprising magnesium stearate, stearic acid, calcium stearate, zinc stearate, sodium stearyl fumarate, hydrogenated castor oil, hydrogenated vegetable oil, light mineral oil, mineral oil, polyethylene glycol, sodium benzoate or mixtures thereof.
  • the lubricant is magnesium stearate.
  • the amount of the lubricant is between 0.02% to 2.0% by weight of the total composition.
  • the pharmaceutical composition is in the form of capsule or tablet.
  • the pharmaceutical composition is formulated as tablets including compressed tablets, coated or uncoated tablets, multilayer tablets, mini tablets, bilayer tablet, buccal tablets, sublingual tablets, effervescent tablets, film-coated tablets, orally disintegrating tablets, chewable tablet, dispersing tablet, lozenges or pastilles.
  • the pharmaceutical composition is formulated as film coated tablet.
  • the pharmaceutical composition is formulated as capsule.
  • a process for the preparation of the pharmaceutical composition comprises empagliflozin or salts thereof and linagliptin or salts or crystalline polymorph thereof comprising the following steps: a) Dry mixing empagliflozin, linagliptin and polyvinylpyrrolidone, b) Heating the mixture prepared at step(a) thereby forming an extrudate, c) Cooling the extrudate at step(b), d) Converting extrudates form to granules, e) Adding dibasic calcium phosphate and colloidal silicon dioxide and then mixing, f) Adding magnesium stearate and mixing, g) Then, optionally pressing to form tablet or filling capsules.
  • Example 1 A tablet or capsule prepared by hot melt extrusion
  • Example 2 A tablet prepared by hot melt extrusion
  • Example 3 A tablet prepared by hot melt extrusion A process for example 1 or 2 or 3; a) Dry mixing empagliflozin, linagliptin and polyvinylpyrrolidone, b) Heating the mixture prepared at step(a) thereby forming an extrudate, c) Cooling the extrudate at step(b), d) Converting extrudates form to granules, e) Adding dibasic calcium phosphate and colloidal silicon dioxide and then mixing, f) Adding magnesium stearate and mixing, g) Then, optionally pressing to form tablet or filling capsules.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant un granulé comprenant de l'empagliflozine ou des sels de celle-ci et de la linagliptine ou des sels ou un polymorphe cristallin de celle-ci, le granulé étant obtenu par extrusion à chaud.
EP22917050.1A 2021-12-28 2022-12-26 Composition pharmaceutique d'empagliflozine et de linagliptine traitée par extrusion à chaud Pending EP4456901A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR202121295 2021-12-28
PCT/TR2022/051598 WO2023129050A1 (fr) 2021-12-28 2022-12-26 Composition pharmaceutique d'empagliflozine et de linagliptine traitée par extrusion à chaud

Publications (2)

Publication Number Publication Date
EP4456901A1 true EP4456901A1 (fr) 2024-11-06
EP4456901A4 EP4456901A4 (fr) 2025-12-10

Family

ID=93014666

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22917050.1A Pending EP4456901A4 (fr) 2021-12-28 2022-12-26 Composition pharmaceutique d'empagliflozine et de linagliptine traitée par extrusion à chaud

Country Status (1)

Country Link
EP (1) EP4456901A4 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11020351B2 (en) * 2018-03-26 2021-06-01 Hetero Labs Limited Stable bilayer tablet compositions
EP4076402A1 (fr) * 2019-12-19 2022-10-26 KRKA, d.d., Novo mesto Forme posologique comprenant une solution solide amorphe d'empagliflozine avec un polymère

Also Published As

Publication number Publication date
EP4456901A4 (fr) 2025-12-10

Similar Documents

Publication Publication Date Title
EP1110543B1 (fr) Composition orale d' une dose pour une libération prolongée
WO2019203771A2 (fr) Compositoins pharmaceutiques solides d'administration par voie orale comprenant de la sitagliptine
EP2468268B1 (fr) Composition de combinaison de vildagliptine et de gliclazide
EP4161525A1 (fr) Procédé de préparation d'un comprimé pelliculé comprenant de la linagliptine et de la metformine
WO2019132833A1 (fr) Combinaison à libération modifiée comprenant de la linagliptine et de la metformine
EP2867199B1 (fr) Compositions stables de fésotérodine
EP3731828A2 (fr) Formulations de comprimés comprenant de la metformine et de la sitagliptine traitées par extrusion à chaud
KR20190017690A (ko) 약학 조성물 및 이의 제조방법
EP4061378A1 (fr) Composition pharmaceutique solide comprenant de la dapagliflozine amorphe isolée à partir d'un solvant polaire
WO2020242413A1 (fr) Combinaison comprenant de l'alogliptine et de la metformine
EP4008317A1 (fr) Formulations pharmaceutiques solides de dapagliflozine amorphe
EP4079296A1 (fr) Formulation de comprimé bicouche comprenant de la dapagliflozine amorphe et de la metformine
EP3784672A2 (fr) Formulations de comprimés comprenant de la metformine et de la sitagliptine
EP4456901A1 (fr) Composition pharmaceutique d'empagliflozine et de linagliptine traitée par extrusion à chaud
WO2023129050A1 (fr) Composition pharmaceutique d'empagliflozine et de linagliptine traitée par extrusion à chaud
EP4620522A2 (fr) Combinaison comprenant de la vildagliptine et de la metformine
WO2023234899A1 (fr) Formulation de comprimé bicouche comprenant de l'empagliflozine et de la metformine
EP4008316A1 (fr) Formulation de comprimé revêtu de film comprenant de la dapagliflozine et du chlorhydrate de metformine
EP4008315A1 (fr) Processus pour des formulations de la dapagliflozine et du chlorhydrate de metformine
EP2468267B1 (fr) Composition de combinaison bicouche de vildagliptine et de gliclazide
WO2024263130A1 (fr) Formulation pharmaceutique comprenant de la linagliptine, de la metformine et un inhibiteur de sglt-2
WO2021010924A1 (fr) Composition de comprimé effervescent de sitagliptine
EP4385501A1 (fr) Formulation pharmaceutique comprenant de la linagliptine, de la pioglitazone et un inhibiteur de sglt-2
EP3781261B1 (fr) Compositions pharmaceutiques orales comprenant un inhibiteur de dpp-4
US20250195440A1 (en) Pharmaceutical formulation comprising glucokinase activator and use thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240610

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: APP_62575/2024

Effective date: 20241125

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOVEL ILAC SANAYI VE TICARET A.S.

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20251110

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/7048 20060101AFI20251104BHEP

Ipc: A61K 31/522 20060101ALI20251104BHEP

Ipc: A61K 45/06 20060101ALI20251104BHEP

Ipc: A61K 9/20 20060101ALI20251104BHEP

Ipc: A61K 9/16 20060101ALI20251104BHEP